Winton Group’s Albireo Pharma Inc ALBO Stock Holding History

Winton Group’s Portfolio ALBO Stock Details ALBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-13,242	Closed	-$337K	–	1586
2019 Q4	$337K	Buy	+13,242	New	+$265K	﹤0.01%	1342

Other funds holding ALBO

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Winton Group's ALBO Position: Q1 2020 in Review

Winton Group sold out of Albireo Pharma Inc (ALBO) in Q1 2020, closing a stake of 13,242 shares — an estimated $337K sold.

Winton Group first reported a position in ALBO in Q4 2019 and held it in 1 quarter. The position peaked at $337K in Q4 2019. 69 funds tracked by Wall St. Rank hold ALBO as of Q1 2020.

Winton Group reported no remaining Albireo Pharma Inc position as of Q1 2020 after selling out during the quarter.
Winton Group sold 13,242 Albireo Pharma Inc shares in Q1 2020, an estimated $337K.
Winton Group first reported a position in Albireo Pharma Inc in Q4 2019 and held it in 1 quarter.
Winton Group's Albireo Pharma Inc position peaked at $337K in Q4 2019.
69 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2020.

Based on Winton Group's 13F filing for Q1 2020, filed 11 May 2020.